Dirk Brockstedt

Dirk Brockstedt

Company: Rapt Therapeutics

Job title: CSO


Developing a Highly Potent & Selective CCR4 Small Molecule Antagonist FLX475 to Target Treg Selectively in the TME 12:30 pm

Discussing current challenges to effectively target regulatory T cells in the TME Deploying a computational biology and large dataset approach to drug development and patient selection strategies Review of clinical status of FLX475Read more

day: Day Two | Track B | Afternoon

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.